Literature DB >> 1889498

Ventilation-perfusion inequality in patients with non-alcoholic liver cirrhosis.

G Hedenstierna1, C Söderman, L S Eriksson, J Wahren.   

Abstract

Ventilation-perfusion relationships were studied in patients with non-alcoholic liver cirrhosis. Spirometry was essentially normal but the transfer factor of the lung (DLCO) was reduced by an average 34% of predicted. Arterial oxygen tension (PaO2) ranged from normal down to 6.9 kPa. Varying degrees of ventilation-perfusion (VA/Q) abnormalities (multiple inert gas elimination technique) were observed with increased dispersion of the perfusion distribution (log SDQ, 0.90; range 0.32-1.71; upper normal limit, 0.60) and the presence of both regions of low VA/Q ratios (between 0.1 and 0.005) (mean 4.1%; range 0-18.8%) and shunt (VA/Q ratios below 0.005) (mean 3.9%; range 0.19.8%). There was a close similarity between measured and calculated PaO2 in normoxaemic patients, but calculated values exceeded measured PaO2 in hypoxaemic patients. The difference between calculated and measured PaO2 correlated inversely to DLCO (r = 0.65, p less than 0.05). An inverse correlation was also noted between DLCO and the sum of shunt and low VA/Q regions (r = 0.87, p less than 0.001). It is concluded that hypoxaemia in non-alcoholic liver cirrhosis patients can be accounted for by intrapulmonary shunting and VA/Q mismatch, and possibly a "diffusion-perfusion" defect in patients with more severe gas exchange impairment.

Entities:  

Mesh:

Year:  1991        PMID: 1889498

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  10 in total

1.  The hepatopulmonary syndrome: new name, old complexities.

Authors:  R Rodríguez-Roisin; A G Agustí; J Roca
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

2.  Effect of oral garlic on arterial oxygen pressure in children with hepatopulmonary syndrome.

Authors:  Mehri Najafi Sani; Hamid-Reza Kianifar; Abdolrazagh Kianee; Gholamreza Khatami
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

3.  [Hepatopulmonary syndrome].

Authors:  G P Glattki; C Maurer; N Satake; R Lange; K Metz; M Wettstein; U Costabel
Journal:  Med Klin (Munich)       Date:  1999-09-15

4.  Lung diffusion capacity in early cirrhosis: is lung diffusion capacity a predictor of esophageal varices and ascites?

Authors:  Jun Young Jung; Dae Won Jun; Jae Hyung Lee
Journal:  Dig Dis Sci       Date:  2010-10-14       Impact factor: 3.199

Review 5.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

6.  Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction.

Authors:  Daniela Wenzel; Michaela Matthey; Laura Bindila; Raissa Lerner; Beat Lutz; Andreas Zimmer; Bernd K Fleischmann
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

7.  Intestinal endotoxemia plays a central role in development of hepatopulmonary syndrome in a cirrhotic rat model induced by multiple pathogenic factors.

Authors:  Hui Ying Zhang; De Wu Han; Ai Rong Su; Li Tong Zhang; Zhong Fu Zhao; Jing Quan Ji; Bao Hong Li; Cheng Ji
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

8.  Hepatopulmonary Syndrome and Post-Liver Transplantation Complications: A Case-Control Study.

Authors:  A Morvan; M Gazon; S Duperret; Z Schmitt; P Pradat; K Mohkam; F Aubrun
Journal:  Int J Organ Transplant Med       Date:  2020

Review 9.  Cardiovascular changes in cirrhosis: pathogenesis and clinical implications.

Authors:  Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2010 Jul-Sep       Impact factor: 2.485

10.  Pulmonary vascular complications of chronic liver disease: Pathophysiology, imaging, and treatment.

Authors:  Ali Nawaz Khan; Hamdan Al-Jahdali; Khalid Abdullah; Klaus L Irion; Quratulain Sabih; Alaa Gouda
Journal:  Ann Thorac Med       Date:  2011-04       Impact factor: 2.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.